Global Valsartan Market Size, Share, and COVID-19 Impact Analysis, By Type (Tablets and Capsules), By Therapeutic Area (Hypertension, Heart Failure, Myocardial Infarction, Diabetic Nephropathy, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 - 2035

Global Valsartan Market Insights Forecasts to 2035

• The Global Valsartan Market Size Was Estimated at USD 1.45 Billion in 2024
• The Market Size is Expected to Grow at a CAGR of around 5.11% from 2025 to 2035
• The Worldwide Valsartan Market Size is Expected to Reach USD 2.51 Billion by 2035
• Asia Pacific is expected to grow the fastest during the forecast period.

According to a Research Report Published by Spherical Insights and Consulting, The Global Valsartan Market Size was worth around USD 1.45 Billion in 2024 and is predicted to Grow to around USD 2.51 Billion by 2035 with a compound annual growth rate (CAGR) of 5.11% from 2025 to 2035. The global market for valsartan is expanding because more people are developing hypertension and heart failure, and because the population is aging and there is a greater need for low-cost generic medication.

Market Overview

The global valsartan market refers to the worldwide industry for valsartan, an angiotensin II receptor blocker (ARB) used mainly to treat hypertension, heart failure and related cardiovascular conditions by relaxing blood vessels and lowering blood pressure. The market experiences growth because more people develop hypertension and cardiovascular diseases, while the global population ages, people learn more about cardiovascular health, and healthcare systems develop better in emerging countries. The wider availability of generic valsartan formulations has made the drug more affordable, while combination therapy and drug delivery innovations create new ways for products to stand out.

The FDA increased its monitoring of ARB impurities in November 2025 after blood pressure drugs that included prazosin faced multiple recalls. The new safety measures require more extensive impurity testing than before to protect patients from cancer risks that developed through earlier valsartan, losartan, and irbesartan issues. The healthcare market in Asia-Pacific and Latin America will experience fast growth because more people will gain access to medical services, and the patient population will increase. The market contains both branded and generic competitors who include Novartis AG, Teva Pharmaceutical Industries Ltd, Mylan, Sun Pharmaceutical Industries and Lupin, who use quality and regulatory standards and wider distribution to build their global market presence.

Report Coverage

This research report categorizes the valsartan market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the valsartan market. Recent market developments and competitive strategies, such as expansion, type launch, development, partnership, merger, and acquisition, have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the valsartan market. 

Driving Factors

The global valsartan market exists because two main factors operate in the market. The first factor that drives market growth relates to increasing heart disease rates, which include hypertension and heart failure. The second factor that drives market growth occurs because more elderly people develop chronic health conditions. People require effective blood pressure maintenance solutions, which drives market growth for single-pill fixed-dose combinations that provide long-term blood pressure control. The demand for healthcare services increases because people develop lifestyle diseases, which include diabetes and obesity. The market undergoes stabilization because stricter rules, better quality control, and high demand for economical generic blood pressure medicines have replaced the past issue of nitrosamine contamination, which caused product shortages and recalls.

Restraining Factors

The global valsartan market faces two major challenges because NDMA carcinogen contamination has resulted in large product recalls, which have created product trust issues and generated legal actions from customers. The market faces obstacles because manufacturing organizations experience strict regulatory checks and budget constraints, which result from patent expirations limiting profit potential, and the market competes with other blood pressure treatment options.

Market Segmentation

The valsartan market share is classified into type, therapeutic area, and distribution channel.  

• The tablets segment dominated the market in 2024, approximately 85% and is projected to grow at a substantial CAGR during the forecast period.

Based on the type, the valsartan market is divided into tablets and capsules. Among these, the tablets segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period. The tablets segment led valsartan market growth because they provide easy administration, are widely available, offer multiple dosage options, are affordable, and patients prefer them. Patients with long-term hypertension and cardiovascular conditions prefer tablets because they help them maintain regular treatment schedules. The product achieves global market leadership through its access points, which include hospitals, retail pharmacies, and online distribution channels.

• The hypertension segment accounted for the largest share in 2024, approximately 60% and is anticipated to grow at a significant CAGR during the forecast period.

Based on the therapeutic area, the valsartan market is divided into hypertension, heart failure, myocardial infarction, diabetic nephropathy, and others. Among these, the hypertension segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period. The hypertension segment grows because hypertension affects a large number of people worldwide, cardiovascular diseases continue to rise, and patients require ongoing treatment. The market for valsartan has grown most in the hypertension segment because people now recognize the condition, and health programs from governments support early detection.

• The retail pharmacies segment accounted for the highest market revenue in 2024, approximately 46% and is anticipated to grow at a significant CAGR during the forecast period.

Based on the distribution channel, the valsartan market is divided into hospital pharmacies, retail pharmacies, online pharmacies, drug stores, and others. Among these, the retail pharmacies segment accounted for the highest market revenue in 2024 and is anticipated to grow at a significant CAGR during the forecast period. The retail pharmacies segment generated the highest market growth because it provides patients with easy access to its products through its widespread locations and operational convenience. Increased sales result from strong prescription fulfillment and the availability of both branded and generic valsartan, and people become more aware of hypertension management. Retail pharmacies remain the primary channel for distributing valsartan globally, which enables continuous market growth.

Regional Segment Analysis of the Valsartan Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the valsartan market over the predicted timeframe.

North America is anticipated to hold the largest share of the valsartan market over the predicted timeframe. North America is expected to become the 38% share of the global valsartan market because of its high rates of hypertension and cardiovascular diseases, combined with its established medical facilities and its strong use of prescribed medications. The United States serves as the primary market driver because public awareness campaigns and extensive health insurance networks enable patients to access both branded and generic versions of valsartan. The Canadian government increases its cardiovascular health programs to support moderate market growth. The market continues to dominate because these countries show advanced clinical practices, their doctors understand them, and their patients follow their treatment plans.

Asia Pacific is expected to grow at a rapid CAGR in the valsartan market during the forecast period. The Asia Pacific valsartan market will experience a 25% share of rapid growth due to rising hypertension rates and increasing cardiovascular diseases, and expanding healthcare facilities, and people will access inexpensive generic medications. The population of China and India drives market expansion through their large patient numbers, government health programs and increasing knowledge about managing chronic health conditions. The 75/25 initiative in India establishes standard care for 75 million people who suffer from hypertension and diabetes by 2025 through its initiatives to enhance screening and primary healthcare services, which will increase demand for valsartan.

The European valsartan market experiences steady growth because of its high cardiovascular disease rates, its growing elderly population, and its established healthcare system. The three countries of Germany, the UK, and France create significant market contributions because their citizens can easily access prescription medications, their government supports hypertension control through various programs, and their people choose to use generic valsartan more frequently. The region experiences market growth because patients now know more about health issues, and they engage in better preventive healthcare behaviours.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the valsartan market, along with a comparative evaluation primarily based on their type of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes type development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Novartis AG
• Teva Pharmaceutical Industries Ltd
• Mylan N.V.
• Hetero Labs Limited
• Sun Pharmaceutical Industries
• Lupin Pharmaceuticals Ltd.
• Torrent Pharmaceuticals Limited
• Aurobindo Pharma Limited
• Zydus Cadila
• Glenmark Pharmaceuticals Inc.
• AstraZeneca plc
• Sandoz International GmbH
• Dr Reddy's Laboratories Ltd.
• Alembic Pharmaceuticals Limited
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Development

• In October 2025, Sandoz Canada announced the launch of PrSandoz Sacubitril-Valsartan, a high-quality, affordable alternative to PrEntresto, approved for all indications. The launch expands Sandoz’s cardiovascular portfolio, supporting its mission to improve patient access to essential heart failure therapies across Canada.

• In January 2025, Lupin Limited announced U.S. FDA approval for its generic Sacubitril and Valsartan tablets in strengths 24/26 mg, 49/51 mg, and 97/103 mg. The approval allows Lupin to market a cost-effective alternative to Entresto, expanding access for heart failure patients.

• In August 2024, while Novartis battles the FDA to protect its heart failure drug Entresto (sacubitril/valsartan) from generics, India’s domestic drug manufacturers are thriving. Generic valsartan sales surge, FDA approvals boost investor confidence, and domestic companies capitalize on the expanding market, signaling a lucrative opportunity.

• In July 2024, Zydus Lifesciences received USFDA approval to market Valsartan Tablets USP (40 mg/320 mg) for hypertension, heart failure, and post-heart attack treatment. Manufactured in Ahmedabad, India, the drug previously recorded annual U.S. sales of USD 149.5 million, expanding Zydus’s cardiovascular portfolio.

• In May 2024, Alembic Pharmaceuticals Ltd gained USFDA final approval for its Sacubitril and Valsartan tablets in strengths 24/26 mg, 49/51 mg, and 97/103 mg. The ANDA is therapeutically equivalent to Entresto, boosting investor confidence as shares rose 0.92%.

• In January 2023, Lupin Limited launched Sacubitril and Valsartan under brand names Valentas and Arnipin in India, available in 50 mg, 100 mg, and 200 mg tablets. The combination targets heart failure patients, addressing a condition affecting an estimated 1.3-4.6 million Indians.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the valsartan market based on the below-mentioned segments:

Global Valsartan Market, By Type

• Tablets
• Capsules

Global Valsartan Market, By Therapeutic Area

• Hypertension
• Heart Failure
• Myocardial Infarction
• Diabetic Nephropathy
• Others

Global Valsartan Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Drug Stores
• Others

Global Valsartan Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa